Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.
Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 ...
Alnylam Pharma’s Promising Clinical Data Tempered by Market Factors in Hold Rating Assessment
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...
Buy Rating Affirmed for Alnylam Pharma on Strong Phase 3 Trial Results and Favorable Sales Forecast
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...
ENDPOINTS NEWS1d
Al­ny­lam agrees to drop patent law­suit against Mod­er­na over Covid-19 vac­cine
Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...
The Pharma Letter5d
New Alnylam HELIOS-B vutrisiran data presented at HFSA
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans
Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...
Benzinga.com9d
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since ...
Investing4d
Alnylam stock holds Buy rating, price target post-data detail
On Tuesday, Canaccord Genuity maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) shares with a steady price target of $366.00. The endorsement comes after Alnylam, alongside BridgeBio ...